What's the difference between testosterone injections, gels, and pellets — which is best?

The three primary TRT delivery methods have different pharmacokinetic profiles and monitoring requirements: injectable testosterone (cypionate or enanthate, 50–100 mg weekly or 100–200 mg biweekly) produces supraphysiological peaks followed by troughs and has the most-studied safety data; transdermal gels (AndroGel, Testim) produce stable daily levels without peaks but carry a skin-transfer risk to female partners or children; subcutaneous pellets (Testopel) are implanted every 3–6 months and produce stable levels without daily adherence requirements but cannot be removed if side effects emerge (Bhasin et al., J Clin Endocrinol Metab, 2010).

From a cardiovascular standpoint, the delivery method with the most clinical outcome data is injectable testosterone, the TRAVERSE trial used injectable testosterone cypionate. Supraphysiological testosterone levels from injections (the "peak" of the peak-trough cycle) are associated with higher erythrocytosis (elevated hematocrit) than other delivery methods, which is the primary polycythemia-driven thromboembolism risk. Weekly injections at lower doses (rather than biweekly higher doses) reduce peak-trough swing and may reduce this risk.

Honesty Scale: Comparative delivery method safety, Promising (2), with injectable having most long-term data. Gel transfer risk, Solid (1) as a real documented risk requiring management protocols.

What to do: Discuss delivery method selection with your prescribing physician based on your lifestyle, preference for stability vs. flexibility, and hematocrit baseline. Monitor hematocrit every 3–6 months on any TRT method, if hematocrit exceeds 54%, clinical dose reduction or phlebotomy is warranted.

For the full picture, read The Testosterone/TRT Deep Dive